Epstein-Barr Virus-Positive Diffuse Large B-cell Lymphoma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
Epstein–Barr virus (EBV)-positive diffuse large B-cell lymphoma (DLBCL) of both younger and elderly population and was defined as EBV-positive monoclonal large B-cell proliferative disease. The survival of patients with EBV-positive DLBCL is significantly worse than that of patients with EBV-negative DLBCL. Cells with latent EBV infection express EBER protein and may express other proteins such as EBNA and LMP proteins. EBV also induces the NFκB pathway, which may be required for the survival of the cells in DLBCL. The immunohistochemical profile is generally positive for B-cell markers CD20, CD19, CD79a, and PAX-5. CD10 and BCL6 are usually negative, while MUM1 is commonly positive. Cases with immunoblastic or plasmablastic features may lack CD20 expression. In situ hybridization for EBER is positive and is considered the most important test in diagnosis, with the highest diagnostic sensitivity. EBV+ DLBCL has a poor response to treatment, so rapid detection is a necessity.
·
The prevalence of EBV positive DLBCL was 14.0%
and 10.4% for EBER cut-off of 20% and 50%, respectively
·
The EBV positive DLBCL of the elderly accounts
for 8.7%–11.4% of all DLBCL in Asian countries, less than 5% in western
nations. Since the introduction of rituximab, R-CHOP has become the standard
treatment for CD20 positive DLBCL.
Thelansis’s “Epstein-Barr
Virus-Positive Diffuse Large B-cell Lymphoma Market Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2021 To 2032" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Epstein-Barr
Virus-Positive Diffuse Large B-cell Lymphoma treatment modalities options for
eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights
of Epstein-Barr Virus-Positive Diffuse Large B-cell Lymphoma across 8 MM market
from the centre of Excellence/ Public/ Private hospitals participated in the
study. Insights around current treatment landscape, epidemiology, clinical
characteristics, future treatment paradigm, and Unmet needs.
Epstein-Barr Virus-Positive Diffuse
Large B-cell Lymphoma Market
Forecast Patient Based Forecast Model (MS. Excel Based Automated
Dashboard), which Data Inputs with sourcing, Market Event, and Product Event,
Country specific Forecast Model, Market uptake and patient share uptake,
Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario,
Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment